newsweek.ro/sanatate/revolutie-oncologie-vaccinul-

A groundbreaking mRNA vaccine developed by Moderna and Merck shows over 40% reduction in cancer recurrence risk, marking a significant advancement in oncology. This personalized vaccine trains the immune system to target cancer cells after surgical removal. The innovative approach shifts from generalized treatments to precision medicine, utilizing genetic sequencing of tumor tissue to create tailored injections. Clinical data indicates a notable decrease in melanoma recurrence and mortality rates, paving the way for further research in other cancer types. However, logistical and economic challenges may hinder widespread implementation in public health systems.